The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Syneron Medical missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased, and GAAP earnings per share contracted to a loss.
Gross margins increased, operating margins shrank, and net margins dropped.
Syneron Medical booked revenue of $61.0 million. The three analysts polled by S&P Capital IQ foresaw sales of $62.5 million. GAAP sales were 14% higher than the prior-year quarter's $53.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.05. The one earnings estimate compiled by S&P Capital IQ predicted $0.04 per share on the same basis. GAAP EPS were -$0.14 for Q4 against $0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.3%, 80 basis points better than the prior-year quarter. Operating margin was -8.1%, 1,910 basis points worse than the prior-year quarter. Net margin was -7.9%, 2,360 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $57.2 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $256.0 million. The average EPS estimate is $0.52.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 743 members rating the stock outperform and 32 members rating it underperform. Among 242 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 237 give Syneron Medical a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is outperform, with an average price target of $18.50.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Syneron Medical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Syneron Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.